Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.[1][2]

Adebrelimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetPD-L1
Clinical data
Drug classAntineoplastic agent
ATC code
Legal status
Legal status
  • Rx in China
Identifiers
CAS Number
PubChem SID
UNII

In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer.[3]

References

edit
  1. ^ Gan Y, Shi F, Zhu H, Han S, Li D (2023). "Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing". Frontiers in Pharmacology. 14: 1241130. doi:10.3389/fphar.2023.1241130. PMC 10398383. PMID 37547339.
  2. ^ "Adebrelimab - Atridia". AdisInsight. Springer Nature Switzerland AG.
  3. ^ "New drugs approved by NMPA in 2023".